Internal Medicine, Nephrology · San Antonio, TX
NPI
1811962723
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4439 E Southcross Blvd, Renal Associates PA
San Antonio, TX, 78222
Phone (210) 359-7888
Groups this clinician bills Medicare through
Medicare paid, 2024
$181K
3,722 services
Medicare patients, 2024
332
Average age 74
Drug cost, 2024
$4.3M
7,840 prescriptions
Company payments, 2025
$2,590
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lisa O Cabrera was code J0885 (injection, epoetin alfa, (for non-esrd use), 1000 units), 1,079 times for 15 patients. In total Lisa O Cabrera billed 3,722 services in 30 codes, and Medicare paid $181K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-07-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 1,079 | 15 | $6.11 | $6,594 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 436 | 77 | $44.61 | $19K |
| 99214 Office E&M - Established | Office | 381 | 181 | $82.86 | $32K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 351 | 180 | $11.17 | $3,922 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 226 | 67 | $34.10 | $7,706 |
| 90960 ESRD Related Services (not dialysis) | Office | 177 | 29 | $247.33 | $44K |
| 90966 ESRD Related Services (not dialysis) | Office | 131 | 27 | $203.24 | $27K |
| 96372 Injection Administration | Office | 128 | 15 | $9.53 | $1,220 |
| 85018 Blood Count | Office | 98 | 15 | $2.28 | $224 |
| 99233 Hospital E&M - Subsequent | Facility | 91 | 60 | $83.46 | $7,595 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 62 | 12 | $44.21 | $2,741 |
| 99232 Hospital E&M - Subsequent | Facility | 26 | 21 | $56.12 | $1,459 |
| 99204 Office E&M - New | Office | 22 | 22 | $108.35 | $2,384 |
| 99496 Chronic, Principal, and Transitional Care Management | Office | 20 | 16 | $163.86 | $3,277 |
| 99223 Hospital E&M - Initial | Facility | 13 | 13 | $123.22 | $1,602 |
By year: 2022 $264K for 3,954 services; 2023 $193K for 4,041 services; 2024 $181K for 3,722 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85018 Blood Count | 98 | 15 | $2.28 | $224 |
Medicare prescription drug claims, 2024
In 2024, the drug Lisa O Cabrera prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 1,153 prescriptions and refills. In total Lisa O Cabrera wrote 7,840 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 1,153 | 1,640 | 271 | $896K |
| Losartan Potassium Generic | 460 | 1,260 | 167 | $3,951 |
| Jardiance Empagliflozin | 449 | 751 | 122 | $446K |
| Ozempic Semaglutide | 422 | 499 | 96 | $443K |
| Furosemide Generic | 421 | 1,080 | 168 | $2,186 |
| Kerendia Finerenone | 328 | 521 | 70 | $323K |
| Lisinopril Generic | 275 | 751 | 104 | $1,598 |
| Velphoro Sucroferric Oxyhydroxide | 244 | 300 | 55 | $837K |
| Spironolactone Generic | 233 | 640 | 91 | $1,852 |
| Allopurinol Generic | 229 | 677 | 95 | $1,677 |
| Lokelma Sodium Zirconium Cyclosilicate | 215 | 263 | 58 | $173K |
| Mounjaro Tirzepatide | 202 | 214 | 43 | $225K |
| Rybelsus Semaglutide | 149 | 237 | 39 | $223K |
| Calcitriol Generic | 138 | 285 | 40 | $2,452 |
| Amlodipine Besylate Generic | 131 | 378 | 56 | $678 |
Brand drugs: 3,849 claims; generic drugs: 3,980 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lisa O Cabrera $2,590 ($2,590 in general payments such as food, travel and fees) from 18 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $537.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 13 | $537 |
| OPKO Pharmaceuticals, LLC | 18 | $361 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $255 |
| Fresenius USA Marketing, Inc. | 11 | $244 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 16 | $218 |
| Amgen Inc. AMGN | 5 | $200 |
| Calliditas Therapeutics US Inc. | 5 | $134 |
| Novo Nordisk Inc NVO | 5 | $133 |
| Ardelyx, Inc. ARDX | 5 | $128 |
| Travere Therapeutics, Inc. TVTX | 5 | $77.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.